Tsikas Dimitrios, Sandmann Jörg, Frölich Jürgen C
Institute of Clinical Pharmacology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 5;772(2):335-46. doi: 10.1016/s1570-0232(02)00121-6.
Highly contradictory data exist on the normal plasma basal levels in humans of S-nitrosoproteins, in particular of S-nitrosoalbumin (SNALB), the most abundant nitric oxide (.NO) transport form in the human circulation with a range of three orders of magnitude (i.e., 10 nM-10 microM). In previous work we reported on a GC-MS method for the quantitative determination of SNALB in human plasma. This method is based on selective extraction of SNALB and its 15N-labeled SNALB analog (S(15)NALB) used as internal standard on HiTrapBlue Sepharose affinity columns, HgCl(2)-catalysed conversion of the S-nitroso groups to nitrite and [15N]nitrite, respectively, their derivatization to the pentafluorobenzyl derivatives and quantification by GC-MS. By this method we had measured SNALB basal plasma levels of 181 nM in healthy humans. It is generally accepted that HgCl(2)-catalysed conversion of S-nitroso groups into nitrite is specific. In consideration of the highly divergent SNALB plasma levels in humans reported so far, we were interested in an additional method that would allow specific conversion of S-nitroso groups into nitrite. We found that treatment with cysteine plus CuSO(4) is as effective and specific as treatment with HgCl(2). The principle of the cysteine/CuSO(4) procedure is based on the transfer of the S-nitroso group from SNALB to cysteine yielding S-nitrosocysteine, and its subsequent highly Cu(2+)-sensitive conversion into nitrite via intermediate.NO formation. Similar SNALB concentrations in the plasma of 10 healthy humans were measured by GC-MS using HgCl(2) (156+/-64 nM) and cysteine/CuSO(4) (205+/-96 nM). Our results strongly suggest that SNALB is an endogenous constituent in human plasma and that its concentration is of the order of 150-200 nM under physiological conditions.
关于人体中S-亚硝基化蛋白,尤其是S-亚硝基白蛋白(SNALB)的正常血浆基础水平,存在高度矛盾的数据。S-亚硝基白蛋白是人体循环中最丰富的一氧化氮(·NO)运输形式,其水平范围达三个数量级(即10 nM - 10 μM)。在之前的工作中,我们报道了一种用于定量测定人血浆中SNALB的气相色谱 - 质谱(GC - MS)方法。该方法基于在HiTrapBlue Sepharose亲和柱上选择性提取SNALB及其用作内标的15N标记的SNALB类似物(S(15)NALB),HgCl₂催化S-亚硝基基团分别转化为亚硝酸盐和[15N]亚硝酸盐,将它们衍生化为五氟苄基衍生物并通过GC - MS进行定量。通过这种方法,我们测定了健康人体中SNALB的基础血浆水平为181 nM。一般认为HgCl₂催化S-亚硝基基团转化为亚硝酸盐具有特异性。考虑到迄今为止报道的人体中SNALB血浆水平差异很大,我们对另一种能够使S-亚硝基基团特异性转化为亚硝酸盐的方法感兴趣。我们发现用半胱氨酸加CuSO₄处理与用HgCl₂处理一样有效且具有特异性。半胱氨酸/CuSO₄方法的原理基于S-亚硝基基团从SNALB转移到半胱氨酸生成S-亚硝基半胱氨酸,随后通过中间产物·NO的形成将其高度敏感地转化为亚硝酸盐。使用HgCl₂(156±64 nM)和半胱氨酸/CuSO₄(205±96 nM)通过GC - MS测量了10名健康人血浆中类似的SNALB浓度。我们的结果强烈表明,SNALB是人体血浆中的内源性成分,在生理条件下其浓度约为150 - 200 nM。